
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/559525/publications.pdf Version: 2024-02-01



<u> Stefan Fdöhlinc</u>

#	Article	IF	CITATIONS
1	BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature, 2017, 551, 384-388.	27.8	261
2	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
3	The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature, 2020, 585, 293-297.	27.8	219
4	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
5	Superior skin cancer classification by the combination of human and artificial intelligence. European Journal of Cancer, 2019, 120, 114-121.	2.8	197
6	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	9.4	189
7	Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. European Journal of Cancer, 2019, 118, 91-96.	2.8	188
8	Pathologist-level classification of histopathological melanoma images with deep neural networks. European Journal of Cancer, 2019, 115, 79-83.	2.8	156
9	Small-molecule-induced polymerization triggers degradation of BCL6. Nature, 2020, 588, 164-168.	27.8	143
10	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 2014, 124, 13-23.	1.4	139
11	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. European Journal of Cancer, 2019, 119, 57-65.	2.8	134
12	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133
13	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
14	Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open, 2016, 1, e000094.	4.5	126
15	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	9.7	125
16	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
17	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. European Journal of Cancer, 2021, 156, 202-216.	2.8	115
18	Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines. Scientific Reports, 2015, 5, 8535.	3.3	111

#	Article	IF	CITATIONS
19	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood, 2016, 127, 2890-2902.	1.4	96
20	Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nature Cell Biology, 2020, 22, 896-906.	10.3	93
21	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood, 2018, 132, 1526-1534.	1.4	90
22	Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood, 2015, 126, 1005-1008.	1.4	88
23	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
24	Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective. Frontiers in Medicine, 2020, 7, 233.	2.6	79
25	Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. European Journal of Cancer, 2021, 155, 200-215.	2.8	70
26	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
27	Stakeholders' perspectives on biobank-based genomic research: systematic review of the literature. European Journal of Human Genetics, 2015, 23, 1607-1614.	2.8	61
28	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. Journal of Physical Education and Sports Management, 2016, 2, a001180.	1.2	57
29	Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. European Journal of Cancer, 2021, 149, 94-101.	2.8	57
30	TelomereHunter – in silico estimation of telomere content and composition from cancer genomes. BMC Bioinformatics, 2019, 20, 272.	2.6	56
31	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nature Medicine, 2020, 26, 992-994.	30.7	56
32	HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization. Cancer Research, 2014, 74, 7125-7136.	0.9	52
33	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncolmmunology, 2017, 6, e1279777.	4.6	50
34	Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. Journal of Medical Internet Research, 2020, 22, e18091.	4.3	45
35	Explainable artificial intelligenceÂin skin cancer recognition: A systematic review. European Journal of Cancer, 2022, 167, 54-69.	2.8	42
36	FUS–DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clinical Cancer Research, 2017, 23, 6227-6238.	7.0	40

#	Article	IF	CITATIONS
37	Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. European Journal of Cancer, 2022, 160, 80-91.	2.8	37
38	Succession of transiently active tumorâ€initiating cell clones in human pancreatic cancer xenografts. EMBO Molecular Medicine, 2017, 9, 918-932.	6.9	36
39	From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Medicine, 2018, 10, 18.	8.2	36
40	Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	1.2	36
41	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. Journal of Medical Internet Research, 2021, 23, e23436.	4.3	36
42	Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. European Journal of Cancer, 2021, 154, 227-234.	2.8	36
43	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. Journal of Medical Internet Research, 2021, 23, e20708.	4.3	35
44	A benchmark for neural network robustness in skin cancer classification. European Journal of Cancer, 2021, 155, 191-199.	2.8	34
45	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications, 2020, 11, 4527.	12.8	32
46	Robustness of convolutional neural networks in recognition of pigmented skin lesions. European Journal of Cancer, 2021, 145, 81-91.	2.8	32
47	Deep learning can predict lymph node status directly from histology in colorectal cancer. European Journal of Cancer, 2021, 157, 464-473.	2.8	32
48	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. Journal of Experimental Medicine, 2017, 214, 2073-2088.	8.5	30
49	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 962-973.	7.0	29
50	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	3.5	29
51	Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Molecular Medicine, 2019, 11, .	6.9	25
52	Overdiagnosis of melanoma – causes, consequences and solutions. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1236-1243.	0.8	23
53	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€~Molecular Diagnostics and Therapy'. European Journal of Cancer, 2020, 135, 1-7.	2.8	23
54	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23

#	Article	IF	CITATIONS
55	Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open, 2019, 4, e000583.	4.5	22
56	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	9.6	22
57	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21
58	<scp>P</scp> albociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein. Protein Science, 2017, 26, 870-879.	7.6	20
59	Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 608-618.	7.0	20
60	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer, 2020, 126, 4032-4041.	4.1	20
61	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	3.0	20
62	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
63	Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death and Disease, 2020, 11, 875.	6.3	17
64	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. Modern Pathology, 2021, 34, 2122-2129.	5.5	17
65	Integrating proteomics into precision oncology. International Journal of Cancer, 2021, 148, 1438-1451.	5.1	15
66	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
67	EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 678966.	2.8	14
68	Stk33 is required for spermatid differentiation and male fertility in mice. Developmental Biology, 2018, 433, 84-93.	2.0	13
69	Exploiting rare driver mutations for precision cancer medicine. Current Opinion in Genetics and Development, 2019, 54, 1-6.	3.3	13
70	Successful BRAF/MEK inhibition in a patient with <i>BRAF</i> <sup>V600E</sup> -mutated extrapancreatic acinar cell carcinoma. Journal of Physical Education and Sports Management, 2020, 6, a005553.	1.2	13
71	Application of precision medicine in clinical routine in haematology—Challenges and opportunities. Journal of Internal Medicine, 2022, 292, 243-261.	6.0	12
72	Genomics of Immunotherapy-Associated Hyperprogressors—Letter. Clinical Cancer Research, 2017, 23, 6374-6375.	7.0	11

#	Article	IF	CITATIONS
73	Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget, 2017, 8, 7678-7690.	1.8	11
74	EORTC SPECTAâ€AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. International Journal of Cancer, 2020, 147, 1180-1184.	5.1	11
75	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology, 2020, 20, 425-432.	1.1	11
76	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open, 2016, 6, e009558.	1.9	9
77	Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis, 2019, 8, 4.	4.9	9
78	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	6.5	9
79	Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. European Journal of Surgical Oncology, 2020, 46, 905-913.	1.0	8
80	Requirement for LIM kinases in acute myeloid leukemia. Leukemia, 2020, 34, 3173-3185.	7.2	8
81	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	2.0	8
82	Outcome after surgical resection of multiple recurrent retroperitoneal soft tissue sarcoma. European Journal of Surgical Oncology, 2021, 47, 2189-2200.	1.0	8
83	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. Cancers, 2020, 12, 3627.	3.7	7
84	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. Journal of Molecular Diagnostics, 2021, 23, 834-846.	2.8	7
85	Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Frontiers in Oncology, 2021, 11, 712944.	2.8	7
86	PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of HSP90. Molecular and Cellular Oncology, 2015, 2, e981444.	0.7	6
87	Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. Journal of Translational Medicine, 2021, 19, 204.	4.4	5
88	BTBBCL6 dimers as building blocks for reversible drug-induced protein oligomerization. Cell Reports Methods, 2022, 2, 100193.	2.9	5
89	Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. European Journal of Cancer, 2017, 83, 142-145.	2.8	4
90	Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes and Cancer, 2020, 59, 106-110.	2.8	4

#	Article	IF	CITATIONS
91	Germline <i>SDHB</i> â€inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes and Cancer, 2020, 59, 601-608.	2.8	4
92	Ruxolitinib is effective in the treatment of a patient with refractory Tâ€ALL. EJHaem, 2021, 2, 139-142.	1.0	4
93	ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Research, 2022, 50, e61-e61.	14.5	4
94	Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery. Oncotarget, 2021, 12, 996-1010.	1.8	3
95	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a001123.	1.2	2
96	Process Evaluation of a Medical Student–Delivered Smoking Prevention Program for Secondary Schools: Protocol for the Education Against Tobacco Cluster Randomized Trial. JMIR Research Protocols, 2019, 8, e13508.	1.0	2
97	Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma. International Journal of Molecular Sciences, 2022, 23, 5174.	4.1	2
98	<scp>MGMT</scp> inactivation as a new biomarker in patients with advanced biliary tract cancers. Molecular Oncology, 2022, 16, 2733-2746.	4.6	2
99	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open, 2020, 5, e000860.	4.5	1
100	Cerebral metastases of a dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2020, 18, 143-145.	0.8	0
101	Recurrent Germline Variant in the Cohesin Complex Gene <i>RAD21</i> Predisposes Children to Lymphoblastic Leukemia and Lymphoma. Blood, 2021, 138, 3358-3358.	1.4	0
102	Interdisciplinary team science to understand and intercept rare cancers. Molecular and Cellular Oncology, 2021, 8, 1997331.	0.7	0
103	TBIO-04. Comprehensive analysis of mutational signatures in pediatric cancers. Neuro-Oncology, 2022, 24, i183-i183.	1.2	0